Development and Evaluation of Aloperine-Loaded Nanostructured Lipid Carriers for the Treatment of Pulmonary Arterial Hypertension
International Journal of Nanomedicine · 2025
DOI: 10.2147/ijn.s489133 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Nanomedicine, 2025. Verfasst von Hui Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Ningxia Medical University, Yinchuan, 750004, People's Republic of China. Hauptthemen laut MEDLINE: Drug Carriers, Lipids, Nanostructures, Pulmonary Arterial Hypertension. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Objective
This study focuses on the development and evaluation of nanostructured lipid carriers (NLCs) loaded with aloperine as a potential therapeutic approach for the treatment of pulmonary arterial hypertension.
Methods
The NLCs were designed to enhance the solubility, stability, and bioavailability of aloperine, a compound with vasodilatory and anti-inflammatory properties. Through a series of experiments including single-factor experimentation, transmission electron microscopy, high-performance liquid chromatography, in vivo pharmacokinetics, and tissue distribution studies, we assessed the physicochemical properties, drug release profiles, and in vitro and in vivo performance of this novel nanocarrier.
Results
The prepared aloperine-loaded NLCs exhibited a milky white and translucent suspension appearance, presenting a quasi-spherical shape under a transmission electron microscope, with an average particle size of (509.48± 30.04) nm and an entrapment efficiency of (64.18± 1.14)%. The drug release profile demonstrated good sustained-release characteristics in vitro, and the formulation remained stable for up to 15 days when stored at 4°C. Compared to the aloperine solution group, the t 1/2 , AUC (0→t) , AUC (0→∞) , MRT (0→t) , and clearance rate of the aloperine-loaded NLCs were 2.3, 2.96, 3.06, 3.03, and 0.22 times higher, respectively. This indicates that formulating aloperine into NLCs can prolong its circulation time in the body. Furthermore, the concentrations of aloperine in the lungs of the NLCs group were 1.79, 3.78, and 2.30 times higher than those in the solution group at three time points (0.25 h, 1.5 h, 4 h), suggesting that NLCs can increase the accumulation of aloperine in the lungs.
Conclusion
Our findings suggest that NLCs loaded with aloperine could offer a promising strategy for the treatment of pulmonary arterial hypertension. Keywords: aloperine, nanostructured lipid carrier, aerosol inhalation, pharmacokinetics
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Ningxia Medical University, Yinchuan, 750004, People's Republic of China.
- General Hospital of Ningxia Medical University, Yinchuan, 750004, People's Republic of China.
- NHC Key Laboratory of Metabolic Cardiovascular Diseases Research, Ningxia Medical University, Yinchuan, 750004, People's Republic of China.
- Ningxia Characteristic Traditional Chinese Medicine Modernization Engineering Technology Research Center, Ningxia Medical University, Yinchuan, 750004, People's Republic of China.
Zitieren
APA
Liu, H., Liu, S., Ma, P., Ma, L., Liu, Y., Zhao, F., & Zhou, R. (2025). Development and Evaluation of Aloperine-Loaded Nanostructured Lipid Carriers for the Treatment of Pulmonary Arterial Hypertension. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s489133
Vancouver
Liu H, Liu S, Ma P, Ma L, Liu Y, Zhao F, et al. Development and Evaluation of Aloperine-Loaded Nanostructured Lipid Carriers for the Treatment of Pulmonary Arterial Hypertension. International Journal of Nanomedicine. 2025. doi:10.2147/ijn.s489133
BibTeX
@article{Liu2025,
author = {Liu, Hui and Liu, Siyun and Ma, Pengsheng and Ma, Long and Liu, Yuxin and Zhao, Fang and Zhou, Ru},
title = {Development and Evaluation of Aloperine-Loaded Nanostructured Lipid Carriers for the Treatment of Pulmonary Arterial Hypertension},
journal = {International Journal of Nanomedicine},
year = {2025},
doi = {10.2147/ijn.s489133}
}
EUVIMED